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Background: Neural tube defects (NTDs), which are among the most common congenital malformations, are
influenced by environmental and genetic factors. Low maternal folate is the strongest known contributing factor,
making variants in genes in the folate metabolic pathway attractive candidates for NTD risk. Multiple studies have
identified nominally significant allelic associations with NTDs. We tested whether associations detected in a large
Irish cohort could be replicated in an independent population.
Methods: Replication tests of 24 nominally significant NTD associations were performed in racially/ethnically
matched populations. Family-based tests of fifteen nominally significant single nucleotide polymorphisms (SNPs)
were repeated in a cohort of NTD trios (530 cases and their parents) from the United Kingdom, and case–control
tests of nine nominally significant SNPs were repeated in a cohort (190 cases, 941 controls) from New York State
(NYS). Secondary hypotheses involved evaluating the latter set of nine SNPs for NTD association using alternate
case–control models and NTD groupings in white, African American and Hispanic cohorts from NYS.
Results: Of the 24 SNPs tested for replication, ADA rs452159 and MTR rs10925260 were significantly associated with
isolated NTDs. Of the secondary tests performed, ARID1A rs11247593 was associated with NTDs in whites, and
ALDH1A2 rs7169289 was associated with isolated NTDs in African Americans.
Conclusions: We report a number of associations between SNP genotypes and neural tube defects. These
associations were nominally significant before correction for multiple hypothesis testing. These corrections are
highly conservative for association studies of untested hypotheses, and may be too conservative for replication
studies. We therefore believe the true effect of these four nominally significant SNPs on NTD risk will be more
definitively determined by further study in other populations, and eventual meta-analysis.
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Neural tube defects (NTDs) are common, severe birth
defects that affect the development of the spinal cord
and/or brain. NTDs mainly present as spina bifida,
anencephaly and encephalocele. Although the NTD rate
has been reduced in areas with folic acid fortification
[1-4], reported NTD rates include ~1 in 1000 births in
the US [5,6], 0.1-1.1 in 1000 births in Europe [7], 1–4.8
in 1000 pregnancies in China [3], 3.9-8.8 in 1000 births
in India [8], and 0.2-9.6 in 1000 births in Latin America
[9]. Both environmental and genetic factors are involved
in the development of NTDs. In western countries, diet-
ary folate is the strongest known environmental factor.
Mothers with an NTD pregnancy have significantly
lower levels of folate [10], and periconceptional folate
supplementation can lower NTD risk by 50-70% [3,11,12].
The most firmly established genetic factor is a common
polymorphism (rs1801133, c.677C > T) in the 5, 10-
methylene-tetrahydrofolate reductase (MTHFR) gene. The
alternate nucleotide in this single nucleotide polymorphism
(SNP) changes an alanine to a valine (p.A222V), resulting
in a thermolabile form of the protein [13]. The MTHFR
c.677 TT genotype has been significantly associated with
NTD cases in many populations (reviewed in [14,15]).
Other NTD risk SNPs have been identified in a number
of populations (e.g., rs2236225 (c.1958G > A, p.R653Q)
in methylenetetrahydrofolate dehydrogenase (NADP +
dependent) 1, methenyltetrahydrofolate cyclohydrolase,
formyltetrahydrofolate synthetase (MTHFD1) [16-21],
rs1805087 (c.2756A > G, p.D919G) in methionine syn-
thase (MTR) [15,16,22-29], rs1051266 (c.80A > G, p.
H27R) in the reduced folate carrier (RFC1/SLC19A1)
[15,21,30-33]), and rs70991108 (19 bp indel; c.86 +
59_86 + 60insACCTGGGCGGGACGCGCCA) in dihy-
drofolate reductase (DHFR) [34-36]). The majority of
associations have not been subjected to robust replication.
Rigorously establishing genetic risk for any multifac-
torial disorder is important but inherently difficult.
Genetic risk is optimally detected with a large number
of racially/ethnically homogenous samples that include
cases with a well-defined, highly penetrant phenotype.
These are difficult criteria to meet for rare, complex
disorders, meaning that statistical power is often com-
promised to some extent. This, in combination with the
bias that significant associations are more likely to be
published [37-40], contributes to many associations in
the literature that would not survive correction for
multiple tests.
Specifically in the field of genetic risk for NTDs, studies
including large numbers of candidate polymorphisms and/
or genes have implicated many candidate SNPs exhibiting
nominal NTD associations [21,41-45]. Each of the cited
studies examined a minimum of 37 SNPs for NTD risk,
yet only the association of rs1907362 in cubilin (CUBN)with NTDs survived correction in the original study [21].
The most likely explanation is that the reported nominally
significant associations were due to chance. However, the
large number of tests performed, reduced power due to
limited availability of samples, and/or the population-
specific effect of a risk allele can all contribute to Type II
errors. Therefore replication studies are essential for the
validation of any genetic risk factor for NTDs.
In one of the largest studies to date we previously
reported evaluation of the common genetic variation in
82 candidate genes for NTD risk in an Irish population
[45]. The inclusion of 570 NTD cases (~95% spina bifida
cases), their parents and 999 controls made it possible to
use both family based methods (the transmission dis-
equilibrium test and log-linear analysis) and case–con-
trol based methods (logistic regression) to evaluate
genetic risk for NTDs in cases (case effect) as well as
genetic risk for an NTD pregnancy in mothers (maternal
effect). In the current study, we test 24 of the resulting
nominally significant association signals using 9 case–
control tests and 14 family-based tests in racially/ethnic-
ally similar populations. The 9 SNPs that showed nominal
significance by case–control analysis in the previously
studied Irish NTD cohort were additionally evaluated for
NTD risk using varying models in racially/ethnically
similar and distinct populations.
Methods
Statistical methods
For replication analyses, each candidate risk allele was
retested using the same association test and model for
which it was nominally significant in the primary study.
These tests are noted in Tables 1 and 2, and include: 1)
case–control tests of logistic regression using a continu-
ous, recessive or dominant genetic model; 2) log-linear
tests of case or maternal effect using a dominant or re-
cessive genetic model; and 3) the Spielman transmission
disequilibrium test (TDT [46]).
Secondary hypotheses involved more broadly testing
the candidate SNPs for NTD risk in other populations
and/or NTD classifications. Three models (continuous,
recessive and dominant) of logistic regression were
performed to generate genotype relative risks (GRRs)
and 95% confidence intervals (CI).
Study populations
Family-based replication was performed in a United
Kingdom cohort consisting of trios of NTD cases and
their parents. Exclusion of the “Other NTDs” class,
which may include a small number of families with mul-
tiple defects or spina bifida occulta, did not substantially
change the results. This cohort consists of three groups
(Table 3). First, the 400 case families recruited with the
assistance of the UK Association for Spina Bifida and
Table 1 Case–control replication analyses in the New York State NTD cohort
Gene SNP Test/Model* Result in Irish NTD Cohort [45] Result in NYS NTD Cohort
GRR [95% CI], p-value GRR [95% CI], p-value
ADA rs6031682 LR CC Dom 0.67 [0.52-0.86], p = 0.0016 0.92 [0.63-1.33], p = 0.653
ALDH1A2 rs7169289 LR CC Dom 0.71 [0.56-0.90], p = 0.0043 1.07 [0.77-1.47], p = 0.697
ARID1A rs11247593 LR CC Cont 1.35 [1.11-1.64], p = 0.0027 0.81 [0.63-1.04], p = 0.092
CDKN2A rs7041637 LR CC Cont 0.69 [0.53-0.89], p = 0.0048 1.07 [0.85-1.36], p = 0.564
CTH rs12733999 LR CC Rec 0.57 [0.39-0.84], p = 0.0048 1.12 [0.65-1.92], p = 0.692
ENOSF1 rs1059384 LR CC Rec 1.84 [1.23-2.75], p = 0.0028 0.98 [0.60-1.60], p = 0.937
FOLH1 rs383028 LR CC Cont 0.58 [0.39-0.85], p = 0.0051 1.07 [0.76-1.52], p = 0.697
MFTC rs17803441 LR CC Cont 0.62 [0.48-0.81], p = 0.0003 1.02 [0.66-1.58], p = 0.922
MTHFD1L rs2295083 LR CC Rec 0.60 [0.43-0.85], p = 0.0038 1.25 [0.89-1.76], p = 0.193
*LR CC = logistic regression, case–control; genetic models: Dom (dominant), Cont (continuous) and Rec (recessive).
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described elsewhere [47]. Second, 131 case families were
recruited from Northern Ireland. Ethical approval of the
use of these samples was granted by the UK Multi-
Centre Research Ethics Committee (University of Newcastle,
UK, and University of Northern Ireland, Coleraine) and the
Institutional Review Board at the National Human Genome
Research Institute (Bethesda, MD, USA).
Replication of findings from case–control analyses was
performed in a NYS case–control cohort. NTD cases
from the entire state born 1998–2005 were identified by
their inclusion in the NYS Congenital Malformations
Registry (NYSCMR). Matched controls were selected as
a random sample of non-malformed control infants born
1998–2005 from NYS Newborn Screening ProgramTable 2 Family-based replication analyses in the combined U
Gene SNP Test/Model* Resu
GRR
ADA rs452159 LL Case Dom 2.28
CDKN2A rs3218009 LL Mat Dom 2.32
COMT rs174675 LL Case Dom 0.41
CUBN rs11254375 LL Mat Dom 1.48
DNMT3A rs7560488 LL Case Rec 2.10
DNMT3B rs6058896 TDT 1.88
FOLH1 rs16906205** LL Mat Dom 0.43
GART rs2070388 TDT 0.53
GNMT rs9462856 LL Case Dom 0.55
MAT2B rs17535909 LL Case Rec 1.69
MTHFD1 rs11627525 LL Mat Rec 2.17
MTHFD1 rs2236225 LL Case Dom 1.66
MTR rs10925260 LL Case Rec 0.64
PEMT rs4646402 LL Case Dom 0.60
PEMT rs16961845 LL Mat Rec 1.92
*LL; = log-linear analysis; TDT = transmission disequilibium test; Case = case effect; M
**Proxy SNP (FOLH1 rs11040291; r2 = 1 in Hapmap CEU) results shown for replicatiorecords. Demographic data was obtained by matching to
NYS birth certificates. Four controls matched for mater-
nal race/ethnicity were selected for each NTD case. Due
to low numbers, the Asian and “other” racial/ethnic sub-
groups were excluded, and subjects coded as “Hispanic,
white” and “Hispanic, other” were combined into a single
Hispanic group for analysis. Case diagnoses allowed
classification of the NTDs into six subgroups based on
NTD subtype (anencephaly, encephalocele, spina bifida)
and whether the NTD was isolated or part of multiple
defects (Table 4). To perform the replication analyses,
only isolated NTDs of all three subtypes among the
NHWs were considered in order to most closely match
the composition of the NTD cases in the original Irish
cohort. Secondary hypotheses involved analyses of: 1) allnited Kingdom NTD cohort
lt in Irish NTD Cohort [45] Result in UK Cohort
[95% CI], p-value GRR [95% CI], p-value
[1.29-4.05], p = 0.0047 1.86 [1.01-3.40], p = 0.045
[1.45-3.71], p = 0.0004 1.16 [0.81-1.65], p = 0.418
[0.23-0.73], p = 0.0028 0.89 [0.55-1.43], p = 0.621
[1.10-1.99], p = 0.0097 1.22 [0.89-1.66], p = 0.210
[1.31-3.38], p = 0.0021 0.89 [0.61-1.28], p = 0.520
[1.24-2.85], p = 0.0029 1.18 [0.77-1.82], p = 0.443
[0.23-0.78], p = 0.0060 1.10 [0.75-1.63], p = 0.619
[0.36-0.78], p = 0.0012 0.73 [0.52-1.03], p = 0.070
[0.36-0.83], p = 0.0048 1.19 [0.85-1.68], p = 0.308
[1.18-2.42], p = 0.0045 Failed genotyping
[1.24-3.79], p = 0.0067 1.13 [0.76-1.68], p = 0.545
[1.16-2.37], p = 0.0054 1.21 [0.84-1.74], p = 0.299
[0.48-0.86], p = 0.0031 0.71 [0.53-0.94], p = 0.019
0 [0.46-0.8], p = 0.0005 0.92 [0.70-1.23], p = 0.585
[1.18-3.11], p = 0.0082 0.73 [0.46-1.15], p = 0.171
at = maternal effect; genetic models: Dom (dominant) and Rec (recessive).
n.





Spina bifida 331 122 26 479
Encephalocele 7 5 1 13
Spina bifida and Encephalocele 2 0 0 2
Other NTDs* 28 4 5 37
Total NTD Cases 368 131 32 531
NTD Mothers 321 121 30 472
NTD Fathers 263 105 21 389
*May include NTD in the context of multiple defects or spina bifida occulta.
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and 2) isolated spina bifida cases and corresponding
matched controls. Approval for the use of the de-
identified samples was granted by the New York State
Department of Health Institutional Review Board and the
NIH Office for Human Research Protections.
Genotyping
MTHFD1 rs2236225 was genotyped in the UK cohort as
a restriction fragment length polymorphism (PCR-RFLP)
using MspI as previously described [17,48]. Genotypes
were obtained for 91.6% of NTD fathers, 92.5% of NTD
cases and 93.6% of NTD mothers. Concordance was
100% for repeated (n = 83) and for re-plated (the testing
of a second sample from the DNA source) (n = 92)
samples using an independent assay based on detection
of allele-specific primer extension using matrix-assisted
laser desorption/ionization – time of flight (MALDI-
TOF) mass spectrometry (Sequenom, San Diego, CA,
USA). The remaining SNPs in Table 2 were also geno-
typed in the UK cohort using the Sequenom platform.
Two independent assays of folate hydrolase (FOLH1)
rs16906205 failed, so the proxy FOLH1 rs11040291 (r2 = 1
in Hapmap CEU) was genotyped and reported instead.
Two independent assays to genotype methionine adenosyl-
transferase II, beta (MAT2B) rs17535909, were attempted
but both failed, and there was no proxy for this singletonTable 4 Number of NTD cases and controls by race/ethnicity
White, non-Hispanic AA, non-Hispanic
Isolated anencephaly 7 2
Isolated encephalocele 22 10
Isolated spina bifida 161 65
Anencephaly - multiple defects 2 3
Encephalocele - multiple defects 16 5
Spina bifida - multiple defects 25 13
Total NTD cases 233 98
Controls 941 408
*Excluded from analysis due to low numbers.SNP. For this set of 13 SNPs, the average call rates
were ≥96.8% for each family group (NTD cases, NTD
mothers or NTD fathers). Re-plated and re-genotyped
samples covered >18% of the cohort with 99.2% geno-
type concordance for this set of 13 SNPs. The 14 SNPs
typed in the UK cohort exhibited non-Mendelian inher-
itance in <1% of families. These SNPs were also in
Hardy Weinberg Equilibrium (HWE, p > 0.01) for each
family group. Genotypes for families exhibiting non-
Mendelian inheritance and other discordant genotypes
were excluded from analysis.
For NYS samples, DNA was extracted from one
3-mm archived dried blood spot specimen [49] and
whole-genome amplified using a primer extension pre-
amplification method, as described previously [50]. SNPs
were genotyped by KBiosciences (Herts, UK) using KAS-
Par chemistry. Eight SNPs were genotyped in duplicate
using independently whole-genome amplified DNA ali-
quots with 100% concordance in genotype calls. FOLH1
rs383028 was genotyped using genomic DNA because
data from amplified DNA did not pass quality control cri-
teria. The average call rate for 9 SNPs (Table 1) was 99.9%
for both cases and controls. Replated samples covered
6.5% of the cohort with genotype concordance of 100%.
No SNPs deviated from HWE (p > 0.01) in any case or
control group for any race/ethnicity.
Results
The primary aim of this study was to perform replication
analyses of the nominally significant NTD associations
identified in a recent study in an Irish population [45].
The secondary aim was to test a subset of these candi-




The replication strategy was designed to retest nomin-
ally significant NTD-associated SNPs in racially/ethnic-
ally matched populations using the same association
tests and genetic models that previously yielded thein the NY state cohort
Hispanic, white Hispanic, other Asian* Other/Unknown* Total
1 1 0 0 11
12 5 1 1 51
65 13 16 2 322
1 0 1 0 7
4 1 0 0 26
11 1 2 0 52
94 21 20 3 469
393 87 91 12 1932
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genes tested in an Irish population [45]. Case–control
association tests were performed in a cohort of 190 iso-
lated NTD cases and 941 controls from non-Hispanic
white (NHW) mothers from NYS, and family-based
tests were performed in NTD trios (n = 530) consisting
of NTD cases and their parents from the United Kingdom,
including centers in Northern Ireland, England and
Wales.
The top 25 groups of SNPs sharing high linkage
disequilibrium (LD; D’ > 0.9) with the lowest p-values for
any test were selected for replication (52 SNPs total).
Without access to NTD mothers and corresponding
controls several loci could not be retested. This in-
cluded 9 independent mother-control signals (17 SNPs) in
adenosine deaminase (ADA), alcohol dehydrogenase 1 fam-
ily, member A2 (ALDH1A2), catechol-O-methyltransferase
(COMT), CUBN, MTHFD1, methylenetetrahydrofolate
dehydrogenase (NADP+dependent) 1-like (MTHFD1L), bra-
chyury (T), and transcription factor AP-2 alpha (TFAP2A).
Of the remaining 35 SNPs, the SNP with the lowest
observed p-value was selected for replication testing
whenever SNPs with a minimum p-value for the same
test and model shared high LD (D’ > 0.9). This reduced
the number of tests to 24 (9 case–control tests and 15
family-based tests). Results of these tests are shown in
Tables 1 and 2.
Replication of associations detected in case–control analyses
We used the NTD case samples from NYS to replicate
case effects previously observed in the Irish NTD co-
hort. Each SNP was tested for association with NTDs by
logistic regression with the same genetic model used for
the original observation. No SNP was observed to be sig-
nificantly associated with isolated NTDs in white cases
from NYS (Table 1). This lack of replication was accom-
panied by the corresponding genotype relative risk (GRR)
values indicating an inconsistent effect of the candidate
risk allele to that observed in the original study for eight
of the nine SNPs.
Replication of associations detected in family-based
analyses
Replication analyses of previously observed case or mater-
nal effects detected by log-linear analysis were repeated
with the same genetic model in a combined cohort of NTD
triads from the United Kingdom. Two SNPs showed nom-
inally significant association with NTDs: ADA rs452159 in
a dominant model (GRR = 1.86 [1.01-3.40], p = 0.045), and
MTR rs10925260 in a recessive model (GRR = 0.71 [0.53-
0.94], p = 0.019). In both cases, the magnitude of the effect
and the specific risk allele was similar to the original obser-
vation in the Irish NTD cohort (Table 2). If applied, the
significance of these results would not withstand Bonferronicorrection for multiple tests when considering all SNPs
tested in the current study. In contrast to the case–control
analyses, the direction of effect for the GRRs of these
family-based associations largely agreed between the initial
and replication studies (10 of 14), regardless of significance.Secondary hypotheses - exploratory analyses in new
populations
Applying analyses that yielded nominal associations from
the initial study
In addition to replication, these candidate SNPs were
tested for association in other NTD populations using
various models. The nine SNPs selected for case–control
replication in the NYS cohort were first tested in African
American and Hispanic cases with an isolated NTD and
controls using the same tests and models for which each
SNP had been originally observed to be nominally asso-
ciated in the Irish population (Table 1, 2 tests/SNP). Of
the nine SNPs examined in each of the two racial/ethnic
groups, only one, ALDH1A2 rs7169289, was found to be
nominally associated with isolated NTDs – in African
Americans in a continuous model (GRR = 0.57 [0.34-0.98],
p = 0.041). This “protective” effect is in contrast to the risk
effect seen for this SNP in the Irish cohort using a domin-
ant model.Case–control analyses in all NTD cases vs. isolated Spina
Bifida cases
These SNPs were also tested by performing logistic re-
gression using three genetic models (continuous, domin-
ant and recessive) in all NTD cases and controls in each
of the three racial/ethnic groups (9 tests/SNP). Of these
nine SNPs tested in nine models (N = 81 tests), AT rich
interactive domain 1A (ARID1A) rs11247593 was the only
SNP found to be nominally associated with NTDs – in
non-Hispanic whites in a dominant model (GRR = 0.58
[0.35-0.97], p = 0.037). This protective effect is in contrast
to the risk effect (GRR > 1) seen in the Irish cohort using a
continuous model (Table 1).
Lastly, the same tests were performed in a restricted
subset of isolated spina bifida cases and controls in the
three racial/ethnic groups (9 tests/SNP). These 81 tests
generated two significant findings: ALDH1A2 rs7169289
was nominally associated with isolated spina bifida
cases in the African American population in continuous
(GRR = 0.46 [0.25-0.87], p = 0.017) and dominant (GRR =
0.47 [0.24-0.94], p = 0.033) models. Similarly, a significant
risk effect was observed in the original Irish population,
but not the NYS NHW population (Table 1).
These results are summarized in Table 5. These results
are nominally significant, though would not withstand
Bonferroni correction using the total number of tests as
the correction factor.
Table 5 Nominally significant associations in the New York state cohort - secondary hypotheses
Gene SNP Race/ Ethnicity Freq Risk Allele NTD Test/Model GRR [95% CI], p-value
ALDH1A2 rs7169289 AA 0.17 Isolated NTDs LR Cont 0.57 [0.34-0.98], p = 0.041
ARID1A rs11247593 NHW 0.75 All NTDs LR Dom 0.58 [0.35-0.97], p = 0.037
ALDH1A2 rs7169289 AA 0.17 Isolated SB LR Cont 0.46 [0.25-0.87], p = 0.017
ALDH1A2 rs7169289 AA 0.17 Isolated SB LR Dom 0.47 [0.24-0.94], p = 0.033
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Our study addressed two questions. First, are SNPs that
were nominally significant upon testing for NTD associ-
ation in an Irish population also associated with NTDs
in a similar, independent population? Second, are the
SNPs that were nominally significant upon testing for
NTD association in an Irish population by logistic
regression also associated with NTDs in different racial/
ethnic populations when using a broader range of asso-
ciation tests, genetic models and NTD case groupings?
Our criteria for replication were stringent, and only
performed for a SNP when the same association test and
genetic model could be applied. Because we did not have
samples from mothers of NYS NTD cases, we were un-
able to test for a maternal risk for nine independent
mother-control signals in seven genes. Nine SNPs were
re-tested for a case effect by logistic regression in a
white NTD sample from NYS, and log-linear analyses
were used to re-test ten SNPs for a case effect and five
SNPs for a maternal effect in a UK NTD sample. Of 14
SNPs previously observed to be associated with NTDs
by family-based analysis in an Irish population, two
showed nominally significant NTD association in trios
from the UK (Table 2). ADA rs452159 falls in the first
intron, and is at the border of a D’ block encompassing
the first exon and intron of the gene. MTR rs10925260
is in intron 23 of the gene, and is part of a large block of
D’ LD encompassing the entire gene. Due to their strong
D’ linkage, these nominally significant associations may
reflect a direct signal or that of a causative SNP linked
to the tested SNP(s).
Although none of the 9 SNPs found to be nominally
significant in Irish NTDs were replicated in isolated NYS
white NTD cases, two were nominally associated with
NTDs under different conditions. ARID1A rs11247593
did not replicate by logistic regression using a continuous
model in isolated NTDs (Table 1), but was significant
when all white NTD cases and controls were tested using
a dominant model (Table 5). ARID1A rs11247593 is
intronic and is part of a large D’ block extending over the
entire gene, so the signal may be due to the tested SNP or
a linked causative SNP. In addition, ALDH1A2 rs7169289
was significantly associated with isolated NTDs and iso-
lated spina bifida cases in the African American popula-
tion (Table 5). These results most likely represent a single
association signal as the genetic models (continuous,dominant) and NTD sets (isolated NTDs, isolated SB)
for these analyses overlap. The estimated effects
observed in African American NTD cases from NYS
(Table 5; OR = 0.46-0.57, p = 0.017-0.041) are similar to
the original effect observed in an Irish population
(Table 1; OR = 0.67 [0.52-0.86], p = 0.0016). ALDH1A2
rs7169289 is just downstream of the gene. It falls be-
tween two blocks of D’ LD, and the association signal
may be due to this SNP or a linked SNP in either block.
As was found in the original study, none of the
observed associations in the NYS and UK sample sets
would have survived correction for multiple tests. One
interpretation is that these associations are indeed due
to chance and that the tested SNPs do not contribute to
NTD risk. It is not clear, however, that Bonferroni cor-
rection is appropriate for replication studies. All the tests
performed in this study were clearly based on individual,
a priori hypotheses generated for our initial study and
supported by previous data. Additionally, factors that can
contribute to Type II error should be considered, such as
population stratification and genetic heterogeneity.
The most important factor may be limited sample size,
which compromises the power to detect true associa-
tions. Compared to the number of NTD cases (n ~ 570)
in the original Irish cohort, a limited number of white
NYS isolated NTD cases (n ~ 190) were available in the
current study. With ~530 NTD trios, however, the UK
NTD cohort appears comparable, but this is before tak-
ing into consideration the power required to replicate an
association. Due to the “winner’s curse,” or the tendency
of an initial observation to overestimate the effect size
or significance of a true association, replication studies
generally require larger study sample numbers to detect
the original effect [51,52]. This may explain why the well
known NTD risk allele of MTHFR rs1801133 (T) is not
associated with NTDs by TDT (p = 0.742) in our large
UK NTD cohort. In fact, it is nominally significant as a
protective factor in a recessive model by log-linear ana-
lysis (GRR = 0.663 [0.441-0.997], p = 0.049). Considering
that this association has been replicated in many studies
in other populations supporting its role in NTD risk, it
would be surprising if the MTHFR rs1801133 TT geno-
type does not contribute to NTDs in the UK population.
A lack of replication power and chance seem the most
likely explanations for this failure to replicate, which
must be taken into consideration for the other SNPs
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of any genetic association requires accumulation of evi-
dence over time, involving multiple studies in independ-
ent populations.
Lack of adequate power is a pervasive problem in the
field of NTD genetics. One recent review estimated
that ~1000 cases would be required to attain 80%
power to detect an odds ratio of 2 or under, yet ap-
proximately one quarter of published NTD association
studies used fewer than 100 cases [53]. This problem is
compounded when attempting to evaluate candidate
risk SNPs in less studied populations. While we were
able to examine candidate risk SNPs of interest in
African American and Hispanic populations from NYS,
far fewer cases were available compared to whites (Table 4).
Although some population-based studies have included
African American cases in aggregate analyses of genetic
risk for NTDs [54-56], and there are studies of NTD
risk in African cohorts [57], this is the first report of
candidate NTD SNPs evaluated in an African American
case–control cohort. The nominal association observed
for ALDH1A2 rs7169289 may be real, but needs
confirmation.
Identifying potential NTD risk SNPs has proven much
easier than validating them. A single replication study
is not definitive, and the limited numbers in existing
NTD cohorts may contribute to subsequent underpow-
ered studies failing to confirm reported associations. By
combining data from multiple published studies, meta-
analyses increase power and confidence in whether a
SNP truly contributes to NTD risk. Meta-analyses in-
volving aggregate data from several hundred to several
thousand NTD cases and controls have confirmed
MTHFR rs1801133 (c.677C > T) as a maternal [58] and
case risk factor for NTDs [14,15,58,59]. Although com-
paratively fewer data were available, meta-analyses show
5-methyltetrahydrofolate-homocysteine methyltransferase
reductase (MTRR) rs1801394 (c/66A >G) is a maternal
risk factor for NTDs [60,61], while MTR rs1805087
(c/2756A > G) does not contribute to maternal or case
risk [15,22,60,62]. However, meta-analysis requires a large
amount of data including full genotype information. These
data are absent in publications for the majority of NTD
risk SNPs that show nominal significance. It is therefore
essential to publish all association study data in a format
that allows future meta-analyses to be performed (i.e.,
genotype counts or a way to unambiguously determine
them). As such, we have reported the genotype data for all
24 SNPs tested in our study (Additional file 1: Table S1
and Additional file 2: Table S2).
Conclusions
In summary, this study represents both the effort to valid-
ate nominally significant NTD associations via replication,and to test a subset of these SNPs in alternate NTD
groupings and racial/ethnic populations. The NTD associ-
ations we observed with four SNPs would not have sur-
vived correction for multiple tests. However, we believe it
would be overly severe to apply Bonferroni correction to
ADA rs452159 and MTR rs10925260, which were nomin-
ally significant by strict replication analysis, as well as
ARID1A rs11247593, which was found to be associated by
a different model and expanded definition of NTDs.
Additionally, to our knowledge, this is the first report of a
genetic association with NTDs in African Americans and
so the nominal significance of ALDH1A2 rs7169289 in the
small NYS NTD cohort warrants follow-up. Further
testing in independent populations and meta-analyses are
needed to clarify the role of these and a multitude of
nominally significant SNPs associated with NTDs.
Additional files
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NTD cases, fathers and mothers from the United Kingdom (England, Wales,
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NTD subtype.
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